Eli Lilly lands next-gen pain asset in SiteOne Therapeutics acquisition worth up to $1B
Eli Lilly is expanding its efforts to advance next-generation pain medications. The Big Pharma has sealed a deal to acquire SiteOne Therapeutics, primarily for a non-opioid pain asset ready to enter phase 2 trials.
Eli Lilly is expanding its efforts to advance next-generation pain medications. The Big Pharma has sealed a deal to acquire SiteOne Therapeutics, primarily for a non-opioid pain asset ready to enter phase 2 trials.
